Related Experiment Video

Updated: Aug 15, 2025

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

9.9K

Editorial: Next generation staging in head and neck cancers

N Gopalakrishna Iyer1, Narayana Subramaniam2, Cesare Piazza3

  • 1Department of Head and Neck Surgery, Singapore General Hospital and National Cancer Centre, Singapore and Duke National University of Singapore (NUS) Medical School, Singapore, Singapore.

Frontiers in Oncology
|January 2, 2023
PubMed
Summary

No abstract available in PubMed .

Keywords:
biomarkershead and neck cancermolecular markersprognosisradiomicssquamous cell carcinomastaging

More Related Videos

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

10.5K
Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics
11:28

Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics

Published on: May 11, 2016

8.6K

Related Experiment Videos

Last Updated: Aug 15, 2025

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

9.9K
Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

10.5K
Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics
11:28

Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics

Published on: May 11, 2016

8.6K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

Articles linked to this work by shared authors, journal, and citation graph.

Healing Following Endoscopic Reconstruction of the Anterior Skull Base in Patients With Sinonasal Malignancies.

International forum of allergy & rhinology·2026

Depth of Invasion Predicts Vocal Fold Motility and Muscle Invasion in Glottic Carcinoma.

The Laryngoscope·2026

Evolution of hazard of recurrence and death after surgery for oropharyngeal cancer according to HPV status.

Oral oncology·2026

Craniofacial Resection for Advanced Cutaneous Squamous Cell Carcinoma: Results From the 2nd International Collaborative Case-Series.

Head & neck·2026

Septal flip flap after endoscopic unilateral resection of sinonasal tumors: a multicenter experience of 133 patients.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·2026

Machine learning prognostication in nasopharyngeal carcinoma: a european multicentre analysis of survival and risk of second malignancy.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·2026

Biomarkers for predicting and monitoring the efficacy of cancer vaccines.

Frontiers in oncology·2026

Adenomatoid tumor of the testis in a patient with history of cryptorchidism, male breast cancer, and thymic B2 thymoma: a case report and literature review.

Frontiers in oncology·2026

From dual inhibition to precision selectivity: the molecular rationale and clinical evolution of next-generation PARP1-selective inhibitors in solid tumors.

Frontiers in oncology·2026

Anxiety about recurrence or metastasis after nephrectomy and perspectives on and preferences for adjuvant therapy among patients with renal cell carcinoma in Japan: a cross-sectional web-based survey.

Frontiers in oncology·2026

Initial clinical experience with total Müllerian compartment resection for locally advanced cervical cancer: a single-center preliminary retrospective cohort study and learning-curve analysis.

Frontiers in oncology·2026

Symptom cluster profiles and their impact on quality of life in Chinese patients with prostate cancer undergoing ADT: a cross-sectional study.

Frontiers in oncology·2026

Heat shock protein family D member 1 (HSPD1) modulates ribosome-related pathways and protein synthesis in lung adenocarcinoma.

Molecular and cellular biochemistry·2026

Patient-reported outcomes in clinical trials leading to breast cancer drug approvals: are we making them count?

Breast cancer research and treatment·2026

Sex-specific associations of the bilirubin-to-albumin ratio with lung cancer risk: evidence from Cox regression and causal survival forest analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026

DHRS2 regulates epithelial-mesenchymal transition in breast cancer cells.

Molecular biology reports·2026

Esculin attenuates cholestatic liver injury and fibrosis in bile duct-ligated rats by modulating oxidative stress, inflammatory responses, and fibrogenic mediators.

Molecular biology reports·2026

Prognostic disparities between radioactive iodine-refractory and non-refractory DTC patients: a cohort study on survival rates and independent risk factors.

Future oncology (London, England)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us